Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent...
- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent...
New Mesa campus deepens Strive's roots in Arizona, expands production capabilities, and accelerates job creation as the company surpasses 700,000...
The multi-year partnership launches with focus on epilepsy, rare disease and AISAN FRANCISCO and ATLANTA, Dec. 02, 2025 (GLOBE NEWSWIRE)...
Jaguar's requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia®A novel non-antibiotic approach...
– Eflornithine and lomustine combination doubled progression free survival (PFS) and improved overall survival (OS) in patients with recurrent Grade...
Eligible Medi-Cal members in Contra Costa County can now receive medically tailored grocery bundles from Safeway storesSAN FRANCISCO, Dec. 02,...
Black Book Research launches US Hospital Cyber Resilience 2026 - Volume 2: Identity, Insurance, and Incident Readiness, a free, vendor-neutral...
Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology...
NAPLES, FL / ACCESS Newswire / December 2, 2025 / Stemtech Corporation, the global leader and pioneer in stem cell...
Appointment reinforces clinical and translational depth as Ernexa advances its best-in-class iMSC cell therapy platform into first-in-human trialsCAMBRIDGE, Mass., Dec....
- New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron®-- New Synthetic Process to...
VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company...
~ New U.S. Patent Extends Protection Through 2042 ~~ Patent Allowance Secures Highest Level of Intellectual Property Protection for MPAR®...
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease...
DOWNERS GROVE, IL / ACCESS Newswire / December 2, 2025 / Dr. Sarah Martin, a women's urology specialist at Duly...
Early collaboration supports development of Cornerstone's emerging athlete-performance program and extends NeuralCloud's ECG analytics into sports-science and human performance marketsPilot...
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase...
PolarityBio thanks the clinical trial sites and, most importantly, the participants, for making this milestone in DFU biologic therapy development...
SIOUX FALLS, SD / ACCESS Newswire / December 2, 2025 / Avel eCare is pleased to announce the appointment of...
FUKUOKA, Japan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) ("rYojbaba" or the "Company"), a Japanese labor consulting...